Equities

Lexicon Pharmaceuticals Inc

LX31:BER

Lexicon Pharmaceuticals Inc

Actions
  • Price (EUR)1.17
  • Today's Change-0.029 / -2.42%
  • Shares traded700.00
  • 1 Year change+10.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments17013887
Total Receivables, Net1.010.030.01
Total Inventory0.38----
Prepaid expenses5.132.482.16
Other current assets, total------
Total current assets17714189
Property, plant & equipment, net7.514.373.48
Goodwill, net454545
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.834.52(0.03)
Total assets229194137
LIABILITIES
Accounts payable14109.15
Accrued expenses151210
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total2.570.402.50
Total current liabilities322322
Total long term debt100490
Total debt100490
Deferred income tax------
Minority interest------
Other liabilities, total5.275.421.19
Total liabilities1367723
SHAREHOLDERS EQUITY
Common stock0.250.190.15
Additional paid-in capital1,8631,7091,609
Retained earnings (accumulated deficit)(1767)(1590)(1488)
Treasury stock - common(2.89)(2.06)(7.52)
Unrealized gain (loss)------
Other equity, total0.03(0.43)(0.01)
Total equity93117114
Total liabilities & shareholders' equity229194137
Total common shares outstanding245189149
Treasury shares - common primary issue0.870.491.17
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.